Olutasidenib (NCT07471841)

Name: Olutasidenib trial for IDH1 Mutation (NCT07471841)
Uploaded: 2026-10-31T19:59:56.227Z
Duration: 1 min 14 s
Description: Olutasidenib trial for IDH1 Mutation (NCT07471841). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07471841.

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax: a one-minute explainerNCT074718411 min

Olutasidenib trial for IDH1 Mutation (NCT07471841). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with relapsed or refractory IDH1-mutated acute myeloid leukemia after no more than two treatment lines, including venetoclax. Prior IDH1 inhibitors exclude participation.

The idea: olutasidenib blocks mutant IDH1 to help leukemia cells mature. Patients take 150 milligrams twice daily. After three cycles, azacitidine may be added for inadequate or waning response. Continuing beyond six cycles requires at least a partial response.

This phase 2 study plans 25 patients. Timothy Pardee leads at Atrium Health Wake Forest Baptist in Winston-Salem, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.